DMS • 1 Rope Ferry Road • Hanover, NH 03755-1404 • Voice 603 650-1200 • Fax 603 650-1202 • Toll Free 1 877 DMS 1797
News • Publications • Calendar • Departments • Biomedical Libraries • Computing • Support the School • Directory
| | |
Alan I. Green, M.D.
Title(s):
Raymond Sobel Professor of Psychiatry
Professor of Pharmacology and Toxicology
Chairman, Department of Psychiatry
Department(s):
Pharmacology and Toxicology
Psychiatry
Education:
Columbia College, A.B. 1965
The Johns Hopkins University School of Medicine, M.D. 1969
Programs:
Neuroscience Center at Dartmouth
Program in Experimental and Molecular Medicine
Other
Websites:
http://dms.dartmouth.edu/ncd/
Contact Information:
|
Department of Psychiatry Dartmouth Medical School DHMC- One Medical Center Drive Lebanon NH 03756 |
|
|
Office: Same Phone: 603-650-7549 Fax: 603-650-8415 Email: alan.i.green@dartmouth.edu Assistant: Cassandra L. Wallen Asst. Phone: 603-650-7549 Asst. Email: cassandra.wallen@dartmouth.edu |
|
Selected Publications: |
|
Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Curr Psychiatry Rep. 2004; 6(5):391-9. (view details on MedLine) Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004; 66(2-3):125-35. (view details on MedLine) Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Research. 2004; 128:9-20. (view details on MedLine) Roth R, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism? Curr Psychiatry Rep. 2005; 7(4):283-91. (view details on MedLine) Niznikiewicz MA, Patel JK, McCarley R, Sutton J, Chau DT, Wojcik J, Green AI. Clozapine action on auditory P3 response in schizophrenia. Schizophrenia Research. 2005; 76(1):119-121. (view details on MedLine) Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB, HGDH Study Group. Olanzapine and haloperidol in first-episode psychosis: Two year data. Schizophrenia Research. 2006; 86(1-3):234-243. (view details on MedLine) Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and Co-Occurring Substance Use Disorder. American Journal of Psychiatry. 2007; 164(3):402-408. (view details on MedLine) Green AI, Noordsy DL, Brunette MF, O'Keefe C Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment. 2008; 34(1):61-71. (view details on MedLine) |
|
Professional Interests:
Schizophrenia and comorbid substance use disorder
Neuropharmacology of psychosis
Neuropharmacology of substance use disorder
Early intervention in schizophrenia
Courses Taught:
Psychopharmacology
Graduate and Medical Pharmacology
Neuroscience of Psychiatric Disorders
Grant Information:
R01DA13196 Green (PI) 2000-2008
NIDA
Cannabis and Schizophrenia: Effects of clozapine
The major goal of this study is to determine whether patients with chronic schizophrenia will decrease cannabis and other substance use when treated with clozapine instead of risperidone. The secondary aim is to begin to investigate the process by which clozapine produces its effects. A subsidiary aim assesses whether clozapine will improve the overall outcome of these patients.
Role: PI
R21MH62157 Green (PI) 2001-2009
NIMH
Clozapine, Cannabis and First Episode Schizophrenia
The study will test whether patients with first episode schizophrenia and cannabis use disorder will be more likely to remain abstinent and to have a better outcome if treated with clozapine compared to risperidone.
Role: PI
R21DA019215 Green (PI) 2004-2009
NIDA
Cannabis and Schizophrenia: fMRI Reward Circuit Biomarker
This study seeks to determine whether a monetary probe of brain reward circuitry linked to fMRI can serve as a “biomarker” of the vulnerability of cannabis use disorder in patients with schizophrenia and a “biomarker” of response to clozapine in these patients.
Role: PI
CSP-1027 Green (PI) 2007-2009
NIAAA/VA
Double-Blind, Placebo-Controlled Multicenter Trial of Quetiapine for the Treatment of Alcohol Dependence.
This is a clinical trial to assess the efficacy of quetiapine in the treatment of heavy drinking alcoholics. Dartmouth is one of 5 sites for this study: Dartmouth, University of Virginia, Brown, Boston University and the University of Pennsylvania.
Role: PI
Investigator-initiated Study (Industry) Green (PI) 2008-2010
Ortho-McNeil Janssen Scientific Affairs
Paliperidone and Alcohol Drinking in Rodents
This study seeks to determine the effect paliperidone has on alcohol drinking in rodents.
Role: PI
Investigator-initiated Study (Industry) Green (PI) 2005-2009
Janssen Pharmaceuticals Inc.
Risperdal Consta in the Treatment of Comorbid Alcohol Use Disorder and Schizophrenia
This study, undertaken at 4 national sites and led by the PI, seeks to assess the use of alcohol and other substances over the course of 6 months in patients taking Long-Acting Risperidone (Risperdal Consta) as compared to those treated with oral risperidone.
Role: PI
Copyright © 2009 Trustees of Dartmouth College